肝衰竭若干诊治要点探讨

doi:10.3969/j.issn.1672-5069.2016.03.004

Abstract

Chen Yongping,Xu Lanman. Diagnosis and management of patients with hepatic failure: What's going on？[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 266-269.

[1] Blachier M，Leleu HM，Radosavljevic P，et al. The burden of liver disease in Europe:a review of available epidemiological data. J Hepatol，2013，58（3）:593-608.
[2] Wang X，Ning Q. Immune mediated liver failure. EXCLI
J，2014，13:1131-1144.
[3] Marra F，Aleffi S，Galastri S，et al. Mononuclear cells in liver fibrosis. Semin Immunopathol，2009，31（3）:345-358.
[4] Hammerich L，Heymann F，Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol，2011，2011:345803.
[5] Awasthi A，Kuchroo VK. Th17 cells:from precursors to players in inflammation and infection. Int Immunol，2009，21（5）: 489-498.
[6] Zhai S，Zhang L，Dang S，et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure. Viral Immunol， 2011，24（4）:303-310.
[7] Niu YH，Yin DL，Liu HL，et al. Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure. World J Gastroenterol，2013，19（26）:4146-4154.
[8] Xu L，Gong Y，Wang B，et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis:regulation of Treg/Th17 cells. J Gastroenterol Hepatol，2014，29（8）:1620-1628.
[9] Sarin SK，Kedarisetty CK，Abbas Z，et al. Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver （APASL） 2014. Hepatol Int，2014，8（4）:453-471.
[10] Martin AP，Bartels M，Hauss J，et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc，2007，39（10）:3169-3174.
[11] Duan BW，Lu SC，Wu JS，et al. Model for end-stage liver disease（MELD） score does not predict outcomes of hepatitis B-induced acute-on-chronic liver failure in transplant recipients. Transplant Proc，2014，46（10）:3502-3506.
[12] Duseja A，Choudhary NS，Gupta S， et al. APACHE II score is superior to SOFA，CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure （ACLF）. J Dig Dis，2013，14（9）:484-490.
[13] Zheng MH，Shi KQ，Fan YC，et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol，2011，9（4）:351-356 e353.
[14] Zheng MH，Shi KQ，Lin XF，et al. A model to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure using artificial neural network. J Viral Hepat，2013，20（4）:248-255.
[15] Zheng MH，Wu SJ，Shi KQ，et al. Conditional survival estimate of acute-on-chronic hepatitis B liver failure:a dynamic prediction based on a multicenter cohort. Oncotarget，2015，6（27）:23261-23271.
[16] Bianchi G，Marzocchi R，Lorusso C，et al. Nutritional treatment of chronic liver failure. Hepatol Res，2008，38（ Suppl 1）:S93-S101.
[17] Chen RC，Xu LM，Du SJ，et al. Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function，balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett，2016，241:103-110.
[18] Tsien CD，McCullough AJ，Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol，2012，27（3）:430-441.
[19] Hwang JP，Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol，2014，11（4）:209-219.
[20] Kusumoto S，Tanaka Y，Mizokami M，et al. Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy. Hepatology，2014，60（2）:765-766.
[21] Zoulim F，Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol，2008，48（Suppl 1）:S2-19.
[22] Larson AM. Diagnosis and management of acute liver failure. Curr Opin Gastroenterol，2010，26（3）:214-221.
[23] Sarin SK，Choudhury A. Acute-on-chronic liver failure: terminology，mechanisms and management. Nat Rev Gastroenterol Hepatol，2016，13（3）:131-149.
[24] Bernardi M，Ricci CS，Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol，2014，4（4）:302-311.
[25] Bernal W，Hall C，Karvellas CJ，et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology，2007，46（6）:1844-1852.
[26] Braissant O，McLin VA，Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis，2013，36（4）:595-612.
[27] Wright G，Vairappan B，Stadlbauer V，et al. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver Int，2012，32（3）:410-419.
[28] Guo LM，Liu JY，Xu DZ，et al. Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int，2003，23 （Suppl 3）:16-20.
[29] McMillin M，Frampton G，Thompson M，et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation，2014，11:121.
[30] Chen G，Shi J，Hu Z，et al. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats:a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm，2008，2008:716458.
[31] Bemeur C，Vaquero J，Desjardins P，et al. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice:antioxidant and anti-inflammatory mechanisms. Metab Brain Dis，2010，25（2）:241-249.

Diagnosis and management of patients with hepatic failure: What's going on？

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[6]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[7]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[8]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[9]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[10]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[11]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[12]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[13]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[14]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[15]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.